Sign in
4

Changes in Ownership

NEKTAR THERAPEUTICS Filed Acc 0001209191-20-031018

Chief R&D Officer sold 4,558 shares at $22.51 ($102,601)

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Zalevsky Jonathan Chief R&D Officer 2020-05-18 Sale −4,558 $22.51 $102,601 322,515 D: show line 1 in the form
Open-market sales · 4,558 sh · avg $22.51 · $102,601
Loading xslF345X03/doc4.xml…